TB & Outbreaks Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB & Outbreaks Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Tuberculosis
Reports from Assiut University advance knowledge in tuberculosis
April 28th, 2009
"A series of fluorinated 1,2,4-triazolo[1,5-a]pyrimidine-6-carboxylic acid derivatives was designed and synthesized as fluoroquinolone analogues," scientists in Assiut, Egypt report. "The synthesized compounds were screened against Mycobacterium tuberculosis H37Rv strain at 6.25 mu g/mL concentration. Compound 4, the 7-oxo-2-(trifluoromethyl)-4,7-dihydro-1,2,4-triazolo[5,1-a]pyrimidine-6-carboxylic acid was found to be a very potent inhibitor, being able to inhibit 92% growth of M. tuberculosis H37Rv at 6.25 mu g/mL concentration," wrote H.M. Abdelrahman and colleagues, Assiut University. The researchers concluded: "At the same time, it proofed to be...
Source: TB & Outbreaks Week (2009-04-28)
|
